

Examiner-Initiated Interview Summary	Application No.	Applicant(s)	
	10/791,152	VAN WEEGHET AL.	
	Examiner	Art Unit	
GAILENE R. GABEL	1641		
All Participants:	Status of Application: _____		
(1) <u>GAILENE R. GABEL</u> .	(3) _____.		
(2) <u>Steffen Soller</u> .	(4) _____.		
Date of Interview: <u>10 September 2008</u>	Time: _____		
Type of Interview:	<input checked="" type="checkbox"/> Telephonic <input type="checkbox"/> Video Conference <input type="checkbox"/> Personal (Copy given to: <input type="checkbox"/> Applicant <input type="checkbox"/> Applicant's representative)		
Exhibit Shown or Demonstrated: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	If Yes, provide a brief description: _____		
Part I.			
Rejection(s) discussed: <i>of record.</i>			
Claims discussed: <i>Claims 12, 17, 21, and 22.</i>			
Prior art documents discussed: <i>of record.</i>			
Part II.			
SUBSTANCE OF INTERVIEW DESCRIBING THE GENERAL NATURE OF WHAT WAS DISCUSSED: <i>See Continuation Sheet</i>			
Part III.			
<input checked="" type="checkbox"/> It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview directly resulted in the allowance of the application. The examiner will provide a written summary of the substance of the interview in the Notice of Allowability. <input checked="" type="checkbox"/> It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview did not result in resolution of all issues. A brief summary by the examiner appears in Part II above.			
(Applicant/Applicant's Representative Signature – if appropriate)			

Continuation of Substance of Interview including description of the general nature of what was discussed: Indicated to Mr. Soller that claims 21 and 22 may be rejoined for allowance. Further indicated to Mr. Soller that claims 12, 17, 21, and 22 need to be amended to clarify that the label for each one of the first antibody and the second antibody of the claimed reagent mixture and kit are different and distinguishably distinct from the other by flow cytometry. Mr. Soller gave the Office authorization to amend claims 12, 17, 21 and 22 in Examiner's Amendment.